Lee A. Norman, MD, MHS, MBA, who spoke at The American Journal of Managed Care®’s Institute for Value-Based Medicine® event on population health March 9, 2023, in Kansas City, Missouri, discusses the shift to value-based care.
Lee A. Norman, MD, MHS, MBA, appeared at The American Journal of Managed Care®’s Institute for Value-Based Medicine® event on population health March 9, 2023, in Kansas City, Missouri, where he discussed the shift to value-based care. He served as the secretary of the Kansas Department of Health and Environment from 2019 to 2021 under Governor Laura Kelly. Norman, who served in the US Air Force and later as a colonel in the Kansas Army National Guard, is currently senior medical director for Optum Care Kansas City.
Transcript
What are some of the key considerations that health care providers need to keep in mind when transitioning to value-based care, and how can they ensure successful implementation?
Yeah, that's a great question. I think a number of things come to mind. One is that the fundamentals of good care have really not changed in a value-based care world. One, as we discussed last week, that evidence-based medical decision-making is critical. And it may sound obvious, but really, there's not a lot of evidence in some areas that we rely on clinical judgment, but where there is evidence for one pathway vs another one: really critical.
The second thing is very fundamental—shared decision-making. The day is here when we have honest and forthright discussions with patients: “This is a likely path that will get you there, this is one that's less likely and more invasive and could actually harm you.” So shared decision-making.
And then finally, I think it's really critical that in fee for service, which is where we've traditionally been practicing for years and years, it's not a matter of all of a sudden one day making a monumental shift to value-based care, where, among other things, there's compensation to the practice for having better outcomes, there's incentives being paid towards members of the health plans or patients—it's a hybrid model. And I think that physicians and other caregivers just need to get comfortable with the idea, it's not going to be a thunderclap where all of a sudden, at the stroke of midnight someday, that it goes from fee for service all the way over to value-based care. We have one foot in the boat and one foot on the dock, and we're having to kind of balance and get accustomed to value-based care.
Prenatal PFAS Exposure Alters Infant Vaccine-Related Immune Cells
August 1st 2025Prenatal exposure to per- and polyfluoroalkyl substances (PFAS), a class of persistent environmental pollutants, was linked to significant shifts in infant T helper cell development, raising concerns about long-term effects on vaccine response, immune regulation, and disease susceptibility.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC
July 31st 2025Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Read More
Advancing Women's Health: CVS Health Leader on Access, Technology, and Breaking Stigmas
December 5th 2024On this episode of Managed Care Cast, we speak with CVS Health's vice president and chief medical officer for women's health and genomics about advancements and challenges in women's health, focusing on care access, technology, and maternal outcomes.
Listen
Linvoseltamab Added as Preferred Agent in Newest MM Practice Guidelines
July 31st 2025On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory multiple myeloma (MM), and the most recent update to the National Comprehensive Cancer Network guidelines for MM has added the BCMA-targeted bispecific antibody as a preferred treatment option.
Read More